China’s biotechnology market has “significantly” driven up the demand for primate experimental models as the market recovers, tightening the supply of laboratory monkeys, according to a leading biotech firm.
Primate experiments typically use monkeys and other non-human species to test the safety and efficacy of a drug under development before clinical trials on humans.
Over US$110 billion worth of Chinese-developed drug candidates were traded in 81 out-licensing deals in the first half of the year, equivalent to 80 per cent of the full-year value in 2025, data from China’s National Medical Products Administration showed.
Joinn added that the price increase resulted from the tightened supply of non-human primates for experimental use in China, as their breeding rate has remained relatively stable.


Don't Miss:
-
Trump slams Australia’s social media crackdown as ‘extortion’
-
Hong Kong a ‘2-way springboard’ between mainland China and world: John Lee
-
Taiwan waits for its new F-16s, still stuck in Hawaii after a fortnight’s delay
-
Singapore police question 5 over racist comments on Nepal floods, Air India investment
-
Travellers in UK face more chaos after air traffic glitch

Khazak President Tokayev’s Influence may extend beyond his Term
Philippines Pushes back as China narrative on Batanes Grows
US-South Korea Alliance Faces a Test beyond Political Rhetoric